Pulmonary hypertension

Pulmonary hypertension is a complex and often progressive condition marked by elevated pressure in the pulmonary arteries, ultimately placing strain on the right ventricle and compromising overall cardiopulmonary function. Its causes range from chronic lung diseases and left heart disorders to thromboembolic events and genetic predispositions. Early symptoms such as fatigue, exertional dyspnea, and chest discomfort are often subtle, contributing to diagnostic delays. Advances in imaging modalities, right heart catheterization, and biomarker testing have improved early recognition and differentiation between the various subtypes. In terms of therapy, pulmonary hypertension management has benefited from the introduction of targeted drugs including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogs, and soluble guanylate cyclase stimulators, all of which improve exercise capacity and delay disease progression. Interventional strategies such as balloon atrial septostomy and lung transplantation are reserved for advanced cases, highlighting the spectrum of therapeutic options. The integration of multidisciplinary care involving pulmonologists, cardiologists, and rheumatologists ensures individualized treatment tailored to underlying etiology. Continued research into molecular pathways and novel biologics offers hope for disease-modifying therapies. Pulmonary hypertension, once considered uniformly fatal, is increasingly managed as a chronic but treatable condition, underscoring the impact of timely intervention and ongoing innovation.